In phase II trials, patients with NASH treated for 12 weeks with the ACC inhibitor, firsocostat (GS-0976), showed reduced circulating ALT, hepatic steatosis and markers of fibrosis (344) mediated by inhibition of hepatic DNL assessed by heavy water labeling (345). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.